Thirty three patients with relapsed FL were treated with GM-CSF 5 μg/kg/day on days 1 to 8 and rituximab 375 mg/m 2 on day 5 of each 21-day cycle for four cycles. Clinical response and tolerability were examined according to international criteria. Biologic monitoring included evaluation of immune cells involved in rituximab activity.
Introduction
Follicular lymphoma (FL) is the most frequently occurring low-grade non-Hodgkin's lymphoma (NHL). 1 Radiation and conventional chemotherapy have not significantly modified its natural history, as patient response is often characterized by remission followed by consecutive relapses until death. Recently, rituximab (a chimeric IgG1 monoclonal antibody directed against CD20) has considerably modified the therapeutic strategy for B lymphoproliferative malignancies. 2 As a single-agent treatment in relapsed indolent lymphoma, rituximab showed a 48% overall response rate (6% complete response [CR] ) with a time to progression of 11.2 months. 3 Randomized trials have demonstrated that rituximab combined with chemotherapy, as well as rituximab maintenance therapy, improves overall response and response duration over chemotherapy alone in patients with recurrent FL. 4, 5 Unfortunately, approximately 50% of patients with low grade NHL exhibit no clinical response to rituximab alone, 3, 6 demonstrating a need for improved knowledge of rituximab's mechanism of action and how that translates into a clinical response.
In vivo mechanisms of rituximab activity are not fully understood, although experimental data suggest that it induces apoptosis, complement-dependent cytotoxicity (CDC), and cellular mechanisms resulting in antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. 7 A more thorough understanding of its mechanisms would aid in improving its efficacy, as the respective contribution of each of these pathways in vivo is difficult to distinguish. However, it has been demonstrated that FL patients who are homozygous for the FCGR3A-158V allele (encoding the FcγRIIIa allotype of highest affinity for IgG1 8 ) have a better response to rituximab. 9 FcγRIIIa is expressed on monocytes and natural killer (NK) cells suggesting an involvement of ADCC in rituximab activity in humans. In contrast, there is a debate whether FcγRIIa-131HR polymorphism actually influences the response to rituximab, 10 despite the fact that FcγRIIa has been involved in the phagocytosis of rituximab-sensitized cells by macrophages. FcγRIIa is also expressed by human granulocytes, and murine models using rituximab have shown the role of neutrophils in the elimination of CD20-expressing tumors, 11 we formulated the hypothesis that granulocyte-macrophage colony-stimulating factor (GM-CSF), which is known to act on these cells, could enhance the clinical activity of rituximab.
GM-CSF belongs to the family of hematopoietic cytokines that can promote myeloid differentiation, as demonstrated by increased granulocyte proliferation and phagocytosis, 13, 14 promotion of macrophage/monocyte ADCC, 15, 16 and enhanced monocyte differentiation into DCs, also known as potent professional antigen-presenting cells. 17, 18 Because GM-CSF has demonstrated effects on the immune system, it is also being currently explored as a vaccine adjuvant in immunotherapy clinical trials. 19 The combined effects of rituximab and GM-CSF were examined in a phase II clinical study in patients with relapsed or progressive FL to evaluate their coordinate clinical and biologic responses and the safety of the immunotherapy combination. 
Patients and Methods

Patients
End points and statistics
The primary efficacy end point was the objective response (OR) rate, ie, the proportion of patients achieving either CR, unconfirmed CR (CRu) or partial response (PR). 21 Clinical response was evaluated at 3 months, and all patients were evaluated for progression every 3 months until progression. Secondary end points were safety and progression-free survival (PFS). PFS was calculated for all patients according to the method of Kaplan and
Meier and was measured from the start of treatment until progression, relapse, or death. 21, 22 For patients who were retreated, response was evaluated at the end of second cycle. Safety and tolerability were assessed using the National Cancer Institute's Common Toxicity Criteria (NCI-CTC). 23 Mann-Whitney nonparametric tests were used to compare cell counts. Patients who stopped treatment early due to toxicity were not included in the PFS analysis.
Results
Patient characteristics
Thirty-three patients were included in the study ( Table 1 showing progressive disease and one patient with stable disease.
Response and outcome
Of 33 patients included in this study, 23 (70%) achieved an OR, including 13 patients (39%) in CR, two (6%) in CRu, and eight patients (25%) in PR. Four patients (12%) stopped treatment early due to toxicity, although one was in CR and three were in PR. Six patients continued treatment for a second course of four cycles. Two patients had improved response from PR to CR, and one patient from SD to PR.
Response rates were 93% (CR + CRu = 60%), 57% (CR + CRu = 57%), and 72%
(CR + CRu = 28%) for low-, intermediate-and high-risk groups, respectively, according to FLIPI (Table 2 ). Median PFS was 16.5 months (range, 1.0 to 57.3; Figure 2A Figure 2B ). Patients with CR (CR + CRu) had a significantly higher PFS (median 34.0 months; range, 6.0 to 57.3) compared with patients with PR (median 7.6 months; range, 3.4 to 46.0) (P < .01, Figure 2C ). The number of cycles did not influence PFS, with a median of 16.4 months (range, 1.0 to 51.9) and 8.3 months (range, 4.5 to 46.9) (P = .8, Figure 2D ).
Although most patients with relapsed FL had received one to three prior therapies, it was noted that a patient who had received seven prior therapies was in CR and achieved 24-month duration of response.
Safety
Four patients stopped treatment early because of a lack of tolerability to GM-CSF (bone pain and erythema at the injection site in two patients), GM-CSF plus rituximab (bone pain and fever in one patient), or rituximab (back pain and hypotension in one patient). Grade 2 to 3 adverse events included fever and pain (four patients), erythema at the injection site (four patients), and mild hypotension (two patients). In a majority of patients symptoms resolved with concomitant corticosteroid treatment.
Biologic follow-up
We first compared peripheral blood cell counts before and after each cycle ( Figure 3 ). We found that rituximab combined with GM-CSF significantly increased white blood cell (WBC), neutrophil, eosinophil, and monocyte counts (P < .001), as well as total lymphocyte counts (P = .03). Immunophenotypic analysis showed that CD14 + cells and pDC counts were also statistically increased after treatment (P < .01 and P = .02, respectively), whereas there was a decrease in mDC counts (P < .01) and circulating B lymphocytes (ie, CD19 + cells) after treatment (P < .01).
When we analyzed mean cell counts according to response status we found that total lymphocyte counts (P = .06,) and mDC counts (P = .04) were increased in CR patients before each cycle, whereas after each cycle we found a significant decrease in pDC counts (P = .01) in CR patients (data not shown). When associated with patient responses, WBCs, neutrophils, eosinophils, monocytes, CD14 + cells, and CD19 + B lymphocytes showed no significant difference between CR and non-CR patients either before or after treatment.
Finally, when we analyzed the ratio of cell counts after versus before treatment according to response, we showed that patients in CR had significantly reduced CD19 + B lymphocyte (P = .03) and pDC (P < .01) cell counts compared with non-CR patients (Figure 4 ).
Discussion
The introduction of rituximab has led to improvements in the standard of care treatments for patients with FL. However, approximately 50% of patients do not respond to frontline rituximab alone, 3, 6 demonstrating a need to improve its efficacy. Given the expected role of FcγRIIIa-and FcγRIIa-expressing cells (including monocytes, DCs and granulocytes) on in vivo rituximab activity and the impact of GM-CSF on these cells, we hypothesized that GM-CSF could potentiate the clinical activity of rituximab.
In this single-institution phase II study, the OR rate (70% with 39% CR) and PFS (median 16.5 months) seen in rituximab-naïve patients with relapsed or progressive FL shows improved efficacy of rituximab combined with GM-CSF. In the pivotal study, which also included rituximab-naïve patients with relapsed FL, McLaughlin et al reported a 60%
OR rate for this histology subgroup with only 6% CR. 3 Although no direct comparison is feasible, rituximab combined with GM-CSF appears to increase the CR rate. Moreover, our results are similar to those noted in interim reports by McLaughlin et al, 25 who cited a 79% OR rate (36% CR) with GM-CSF and rituximab for previously untreated and relapsed patients with indolent NHL. Our positive results are not explained by selection criteria, as the distribution of adverse prognostic factors assessed by the FLIPI index are similar to those found by Solal-Céligny et al. 24 We also found that FLIPI influenced PFS after treatment with rituximab and GM-CSF. The prognostic index was first described for FL at diagnosis, 24 but recent data suggest that FLIPI could also be useful in predicting PFS at relapse. 26 In our study, the quality of response appeared to be significantly associated with outcome, a result also noted by other investigators.
26,27
In the past, extended courses of rituximab monotherapy to eight consecutive weekly cycles rather than the standard four have shown prolonged duration of response in patients with relapsed or refractory low-grade NHL. 28 In this study, improved responses were noted for three patients receiving a second cycle of four courses, suggesting that an additional cycle of therapy should have the potential to improve patient outcome. However, the impact of prolonged treatment on PFS remains to be demonstrated, since PFS for the six patients receiving two cycles was not different compared with patients receiving only one cycle. Even if these results have to be confirmed in a larger cohort, they suggest that patients likely do not benefit from prolonged therapy. Such results have also been seen in another study examining rituximab maintenance therapy compared with retreatment at progression for FL.
29
Examination of the potential biologic basis for this combined efficacy demonstrates that the immunotherapy combination of GM-CSF and rituximab activates numerous immune cells. The increase is notably significant for granulocytes and monocytes, which express FcγRIIIa and FcγRIIa and are potentially involved in rituximab-mediated ADCC and phagocytosis. We have not evaluated ADCC or NK cell count in this study, but Liu and colleagues previously reported that the combination of rituximab and GM-CSF enhanced ADCC in patients with recurrent indolent lymphoma, especially for those in CR, without affecting NK cell activity. 30 Immunophenotypic analysis showed a significant increase in CD14 + cells, a marker typically found on monocytes, macrophages, granulocytes, and DC precursors. The increase in circulating DCs, which make up a very small proportion of peripheral blood, was confirmed by specific analysis. Of the two types of DCs, pDCs are thought to originate from lymphoid precursor cells. 31 We have found that GM-CSF combined with rituximab increased pDC counts. This was associated with a rise in pDC counts in non-CR patients after treatment. It is known that GM-CSF can enhance mDC cells less efficiently than pDC cells, thus affecting the mDC/pDC ratio. 32 This pDC enhancement may favor an increase in regulatory T cells (T reg ), which are known to downregulate antitumor T cells. 33 Unfortunately, the T reg subpopulation was not evaluated in this study because their functional and phenotypic characteristics were poorly known at the time of study initiation. Interestingly, an increase in pDCs was observed as early as following the first cycle of GM-CSF plus rituximab treatment. The increased pDC expression therefore may serve as an early marker of treatment failure, making it possible to prospectively monitor treatment efficacy in upcoming trials.
We found that total lymphocyte counts were significantly increased. Although myeloid effects of GM-CSF are well recognized, its activity on lymphocytes remains largely unknown. As typically observed after rituximab, immunophenotypic analysis showed that B lymphocyte counts were significantly decreased, demonstrating that the increase of lymphocyte counts involved mostly T lymphocytes and/or NK cells. This has been also reported with GM-CSF after conventional 34 or intensified chemotherapy 35 and could be related to an increase of memory T cells. 34 We have found that B lymphocyte counts were significantly less reduced after treatment in non-CR patients compared with CR patients, a result noted in a rituximab pivotal trial 3 that could be due to intrinsic resistance to rituximab.
More than 540,000 patients have been treated with rituximab, and it is generally considered to have an excellent safety and tolerability profile. 36 Our results demonstrated that addition of GM-CSF does not impair tolerance to rituximab in patients with recurrent FL. The capacity of GM-CSF to stimulate immune cells involved in innate and adaptive immunity suggests that there is the potential for long-term benefit in terms of supporting and/or regulating the immune system. Such a combination has also been tested in patients with chronic lymphocytic leukemia 37 or associated with chemotherapy in diffuse large B-cell lymphoma 38 and has demonstrated improved response rates. Rituximab alone could be considered in FL patients with a low tumor burden, 39 for control of minimal residual disease after autologous stem cell transplantation, 40,41 or as maintenance therapy. 4, 5, 42 In this setting, the addition of GM-CSF to rituximab could improved rituximab's response rate and/or residual disease control without increased toxicity.
Furthermore, GM-CSF is a granulocyte growth factor and could therefore provide immunestimulating benefits to dose-intensified immunochemotherapy regimens used in NHL patients.
This single-center study shows that GM-CSF enhances the efficacy of rituximab, with an increased CR rate over rituximab monotherapy (although not directly comparable 
